1,992 Hits in 1.9 sec

CAPABLE D8.1: Market Opportunity Report

Manuel Ottaviano, Enea Parimbelli, Silvana Quaglini, Mor Peleg, Ronald Cornet, Flora Gilboa-Solomon, Valentina Ganicheva, Yoram Lev Yehudi, Szymon Wilk, John Fox, David Glasspool, Laura Del Campo (+4 others)
2020 Zenodo  
The document presents the preliminary results of the exploitation activities of the CAPABLE project. The activities that will be reported in the document are the following: Revision of the challenges for the technologies to improve cancer care Approaches to be used to set up a roadmap for the business development of the CAPABLE project (CEHRES Roadmap) Analysis of the stakeholders that might directly and indirectly benefit from CAPABLE Initial market and competitor analysis First draft of the
more » ... lue proposition Summarize the conclusion of the work drafting a preliminary SWOT analysis Revision of the exploitation opportunities in the project.
doi:10.5281/zenodo.4540536 fatcat:x75flogsbnesrcfm6nkm4kdz6u

Prevalence of Isolated "Pre-Malignant" Lesions on Prostate Biopsy in a Racially Diverse Community Screened Cohort

Michael A. Liss, Donna Ankerst, David Zapata, Javier Hernandez, Robin J. Leach, Ian M. Thompson
2015 Open Journal of Urology  
Liss et al. 214  ...  Michael Liss is funded by DOD PC141535. Ian Thompson is the principal investigator of SABOR funded by U01 CA086402 and P30 CA054174 mechanisms of the National Institutes of Health.  ... 
doi:10.4236/oju.2015.512034 fatcat:spyjhzo33jcl7hqn7hlramomii

CAPABLE D8.2: Market Analysis V2

Manuel Ottaviano, Enea Parimbelli, Silvana Quaglini, Mor Peleg, Ronald Cornet, Savannah Glaser, Flora Gilboa-Solomon, Valentina Ganicheva, Yoram Lev Yehudi, Szymon Wilk, Viola Ghio, Valentina Tibollo (+10 others)
2020 Zenodo  
The document shows the activities of market research performed in the second half of the first year of the project. Differently from the initial deliverable (D8.1): the focus of the market research has been to study the specific costs of kidney and melanoma cancer, and the possible barriers and success criteria to market to then continue the CAPABLE roadmap to the adoption following the CEHRES method presented in D8.1. The document also presents an update of the technology vigilance, which also
more » ... contains a specific selection of solutions that are relevant competitors of CAPABLE and a study of the existing solution in the 2 hospitals of CAPABLE (ICSM and NKI-NVL). The document also presents an updated version of the Consortium IPR strategy and questionnaire interviews to be launched next year to start exploiting interests from key decision makers.
doi:10.5281/zenodo.4540556 fatcat:55nezmtw5fe5rhypqwtf7qna3e

Advanced Glycation End Products: New Clinical and Molecular Perspectives

Juan Salazar, Carla Navarro, Ángel Ortega, Manuel Nava, Daniela Morillo, Wheeler Torres, Marlon Hernández, Mayela Cabrera, Lissé Angarita, Rina Ortiz, Maricarmen Chacín, Luis D'Marco (+1 others)
2021 International Journal of Environmental Research and Public Health  
Diabetes mellitus (DM) is considered one of the most massive epidemics of the twenty-first century due to its high mortality rates caused mainly due to its complications; therefore, the early identification of such complications becomes a race against time to establish a prompt diagnosis. The research of complications of DM over the years has allowed the development of numerous alternatives for diagnosis. Among these emerge the quantification of advanced glycation end products (AGEs) given
more » ... increased levels due to chronic hyperglycemia, while also being related to the induction of different stress-associated cellular responses and proinflammatory mechanisms involved in the progression of chronic complications of DM. Additionally, the investigation for more valuable and safe techniques has led to developing a newer, noninvasive, and effective tool, termed skin fluorescence (SAF). Hence, this study aimed to establish an update about the molecular mechanisms induced by AGEs during the evolution of chronic complications of DM and describe the newer measurement techniques available, highlighting SAF as a possible tool to measure the risk of developing DM chronic complications.
doi:10.3390/ijerph18147236 fatcat:7vhlehbfurgilno7yrijfotjim

Strongyloides sp. resistentes al albendazol y levamisol en búfalos de México

Nadia Florencia Ojeda-Robertos, Atziri Miroshlava Aguirre-Serrano, Rosina Cardenas de la Cruz, Liss Nayelli Hernández-Martínez, Jorge Alonso Peralta-Torres, Alfonso Juventino Chay-Canul, Jorge Alberto Priego-García, Roger Ivan Riodríguez-Vivas
2022 Revista MVZ Cordoba  
José del Carmen Alejo Álvarez, a los estudiantes de MVZ-UJAT, EMVZ Cesar Augusto Hernández Salvador, Pedro Manuel Tosca, Martín Ronaldo Yzquierdo Chable, Paola Jiménez Jiménez y José Rodolfo Frías Macías  ... 
doi:10.21897/rmvz.2227 fatcat:5amyclvybreznojlhfkpykq6gq

The effect of 3-month finasteride challenge on biomarkers for predicting cancer outcome on biopsy: Results of a randomized trial

Javier Hernandez, Jonathan Gelfond, Martin Goros, Michael A. Liss, Yuanyuan Liang, Donna Ankerst, Ian M. Thompson, Robin J. Leach, David J. Handelsman
2018 PLoS ONE  
Finasteride, a 5-alpha reductase inhibitor may have effects on biomarkers such as prostatespecific antigen (PSA) that could be leveraged to improve screening. Objective To determine the predictive characteristics of biomarkers for prostate cancer for cancer on biopsy following 3 months of finasteride use compared with placebo. Design, setting and participants 383 men from multiple clinical sites with intermediate prostate cancer risk, without history of prostate cancer, were randomly allocated
more » ... n a double-blinded manner, 4:1, to receive either finasteride or placebo for 90 days at which time a prostate biopsy was performed. Outcome measurements and statistical analysis The primary outcomes were associations of biomarkers with prostate cancer that were tested using multiple logistic regression and area under the receiver operating curves (AUC). Biomarkers for PCA risk (PCA3, TMPRSS2:ERG (T2:ERG) gene product, and PSA) were measured at baseline and at biopsy in a blinded fashion to assess the predictive performance of baseline levels, 90-day levels, and measures of change relative to standard predictors.
doi:10.1371/journal.pone.0204823 fatcat:v7giuxev3nhbvk7qbgfjfotomy

Multi-cohort modeling strategies for scalable globally accessible prostate cancer risk tools

Johanna Tolksdorf, Michael W. Kattan, Stephen A. Boorjian, Stephen J. Freedland, Karim Saba, Cedric Poyet, Lourdes Guerrios, Amanda De Hoedt, Michael A. Liss, Robin J. Leach, Javier Hernandez, Emily Vertosick (+2 others)
2019 BMC Medical Research Methodology  
Online clinical risk prediction tools built on data from multiple cohorts are increasingly being utilized for contemporary doctor-patient decision-making and validation. This report outlines a comprehensive data science strategy for building such tools with application to the Prostate Biopsy Collaborative Group prostate cancer risk prediction tool.
doi:10.1186/s12874-019-0839-0 pmid:31615451 pmcid:PMC6792191 fatcat:nbspocuyfrhvrdmycozlvxduma

Exploring the Frequency Domain of Continuous Glucose Monitoring Signals to Improve Characterization of Glucose Variability and of Diabetic Profiles

Giuseppe Fico, Liss Hernández, Jorge Cancela, Miguel María Isabel, Andrea Facchinetti, Chiara Fabris, Rafael Gabriel, Claudio Cobelli, María Teresa Arredondo Waldmeyer
2017 Journal of Diabetes Science and Technology  
The use of continuous glucose monitoring (CGM) devices is a relatively new approach in the management of patients with diabetes. These devices measure interstitial glucose concentration continuously (normally every 5 minutes) over a period of 7 days. 1,2 They are used both in open-loop-eg, to detect hypo/hyperglycemic events 3,4 -and closed-loop modalitiesas a key element for artificial pancreas devices. 5-7 The analysis of CGM data allows obtaining more detailed information on glucose
more » ... ty (GV) patterns during the whole day, for example by highlighting unhidden excursions of hyperglycemia, hypoglycemia, pre/postprandial and before-sleep glucose measurements. This information can be used to improve prescription of treatment and insulin dosages. 8-10 In a recent literature research, it was highlighted that many works are focused on the use of the CGM signal identifying indexes to characterize GV. 11 The assessment of GV is important, since it has been proved that abnormal GV could be a risk factor for 685717D STXXX10.1177/1932296816685717Journal of Diabetes Science and TechnologyFico et al research-article2017 Abstract Background: Continuous glucose monitoring (CGM) devices measure interstitial glucose concentrations (normally every 5 minutes), allowing observation of glucose variability (GV) patterns during the whole day. This information could be used to improve prescription of treatments and of insulin dosages for people suffering diabetes. Previous efforts have been focused on proposing indices of GV either in time or glucose domains, while the frequency domain has been explored only partially. The aim of this work is to explore the CGM signal in the frequency domain to understand if new indexes or features could be identified and contribute to a better characterization of glucose variability. Methods: The direct fast Fourier transform (FFT) and the Welch method were used to analyze CGM signals from three different profiles: people at risk of developing type 2 diabetes (P@R), T2D patients, and type 1 diabetes (T1D) patients. Results: The results suggests that features extracted from the FFT (ie, the localization and power of the maximum peak of the power spectrum and the bandwidth at 3 dB) are able to provide a characterization for all the three populations under study compared with the Welch approach. Conclusions: Such preliminary results can represent a good insight for futures investigations with the possibility of building and using new indexes of glucose variability based on the frequency features.
doi:10.1177/1932296816685717 pmid:28627250 pmcid:PMC5588824 fatcat:ujhijqps3vh3ze2bhe7kockq4u

A Contemporary Prostate Biopsy Risk Calculator Based on Multiple Heterogeneous Cohorts

Donna P. Ankerst, Johanna Straubinger, Katharina Selig, Lourdes Guerrios, Amanda De Hoedt, Javier Hernandez, Michael A. Liss, Robin J. Leach, Stephen J. Freedland, Michael W. Kattan, Robert Nam, Alexander Haese (+6 others)
2018 European Urology  
Background-Prostate cancer prediction tools provide quantitative guidance for doctor-patient decision-making regarding biopsy. The widely used online Prostate Cancer Prevention Trial Risk Calculator (PCPTRC) utilized data from the 1990s based on six-core biopsies and outdated grading systems. Objective-We prospectively gathered data from men undergoing prostate biopsy in multiple diverse North American and European institutions participating in the Prostate Biopsy Collaborative Group (PBCG) in
more » ... rder to build a state-of-the-art risk prediction tool. Design, setting, and participants-We obtained data from 15 611 men undergoing 16 369 prostate biopsies during 2006-2017 at eight North American institutions for model-building and three European institutions for validation. Outcome measurements and statistical analysis-We used multinomial logistic regression to estimate the risks of high-grade prostate cancer (Gleason score ≥7) on biopsy based on clinical characteristics, including age, prostate-specific antigen, digital rectal exam, African ancestry, first-degree family history, and prior negative biopsy. We compared the PBCG model to the PCPTRC using internal cross-validation and external validation on the European cohorts. Results and limitations-Cross-validation on the North American cohorts (5992 biopsies) yielded the PBCG model area under the receiver operating characteristic curve (AUC) as 75.5% (95% confidence interval: 74.2-76.8), a small improvement over the AUC of 72.3% (70.9-73.7) for the PCPTRC (p < 0.0001). However, calibration and clinical net benefit were far superior for the PBCG model. Using a risk threshold of 10%, clinical use of the PBCG model would lead to the equivalent of 25 fewer biopsies per 1000 patients without missing any high-grade cancers. Results were similar on external validation on 10 377 European biopsies. Conclusions-The PBCG model should be used in place of the PCPTRC for prediction of prostate biopsy outcome. Patient summary-A contemporary risk tool for outcomes on prostate biopsy based on the routine clinical risk factors is now available for informed decision-making.
doi:10.1016/j.eururo.2018.05.003 pmid:29778349 pmcid:PMC6082177 fatcat:cewn7qqorvdihnrcyqgowqrt3a

CAPABLE D2.2: Requirements Table and Use Case Description

Mor Peleg, Valentina Ganicheva, Giordano Lanzola, Silvia Panzarasa, Enea Parimbelli, Francesca Polce, Silvana Quaglini, Lucia Sacchi, Nicole Veggiotti, Alexandra Kogan, Roy Leizer, Matteo Gabetta (+20 others)
2021 Zenodo  
The aim of this deliverable is to define the requirements of the CAPABLE system. These requirements include clinical requirements regarding the clinical scope of decision-support and its content (knowledge base), patient and clinician user needs, and technical system requirements for the different system components. Following our iterative development approach for the CAPABLE system, this document presents the functional and non-functional requirements. This document opens with a literature
more » ... ew (Section 2, corresponding to Task T2.1) that we have performed to identify the state of the art of data-science-based methods and systems for supporting the quality of life of cancer patients, starting with data collection and data integration methods, and continuing to machine-learning-based prediction models and patient coaching systems. The literature review allowed us to identify best practices that we plan to adopt in the CAPABLE system, as well as open challenges, many of which we plan to address. Going from the state of the art to our own CAPABLE system, in Section 3 we present the overall system architecture, along with the different components of the system. In addition to this structural description of the system, we also provide a workflow presenting the process of care supported by the CAPABLE system, from patient enrollment and initial setup of the physician-facing dashboard and patient-facing mobile app, to the ongoing services provided by the systems to these users, including patient monitoring and decision-support. The following chapters present a description of the methods that we used to collect different requirements, as well as the requirements themselves. Section 4 presents patient requirements (Task T2.1) and Section 5 – clinical requirements (Task T2.3), relating to the needs of the clinicians as well as a selection of clinical practice guidelines, monitoring data to be collected by patients at home, and certification/barriers to market. Section 6 (corresponding to Task T2.6) starts with a set of [...]
doi:10.5281/zenodo.6058986 fatcat:tausjr6lzvexxiq3mdprm5gyie

CAPABLE D2.1: Requirements Table and Use Case Description

Mor Peleg, Giordano Lanzola, Silvia Panzarasa, Enea Parimbelli, Francesca Polce, Silvana Quaglini, Lucia Sacchi, Nicole Veggiotti, Alexandra Kogan, Roy Leizer, Matteo Gabetta, Ronald Cornet (+20 others)
2020 Zenodo  
The aim of this deliverable is to define the requirements of the CAPABLE system. These requirements include clinical requirements regarding the clinical scope of decision-support and its content (knowledge base), patient and clinician user needs and requirements, and technical system requirements for the different system components. Following our iterative development approach for the CAPABLE system, this document presents the majority of the functional and non-functional requirements. Once we
more » ... mplement the system in iterations and have users try out the system, additional requirements may be refined and reported at the end of Year 2.
doi:10.5281/zenodo.4540451 fatcat:vusuh5dh2ze7bk4nlsgdysi3fy

UCX: An Open Source Framework for HPC Network APIs and Beyond

Pavel Shamis, Manjunath Gorentla Venkata, M. Graham Lopez, Matthew B. Baker, Oscar Hernandez, Yossi Itigin, Mike Dubman, Gilad Shainer, Richard L. Graham, Liran Liss, Yiftah Shahar, Sreeram Potluri (+8 others)
2015 2015 IEEE 23rd Annual Symposium on High-Performance Interconnects  
This paper presents Unified Communication X (UCX), a set of network APIs and their implementations for high throughput computing. UCX comes from the combined efforts of national laboratories, industry, and academia to design and implement a high-performing and highly-scalable network stack for next generation applications and systems. UCX design provides the ability to tailor its APIs and network functionality to suit a wide variety of application domains and hardware. We envision that these
more » ... s will satisfy the networking needs of many programming models such as the Message Passing Interface (MPI), OpenSHMEM, Partitioned Global Address Space (PGAS) languages, task-based paradigms, and I/O bound applications. To evaluate the design we implement the APIs and protocols, and measure the performance of overhead-critical network primitives fundamental for implementing many parallel programming models and system libraries. Our results show that the latency, bandwidth, and message rate achieved by the portable UCX prototype are very close to that of the underlying driver. With UCX, we achieved a message exchange latency of 0.89 us, a bandwidth of 6138.5 MB/s, and a message rate of 14 million messages per second. As far as we know, this is the highest bandwidth and message rate achieved by any network stack (publicly known) on this hardware.
doi:10.1109/hoti.2015.13 dblp:conf/hoti/ShamisVLBHIDSGL15 fatcat:63cwg7qguvfp5olammokrdk7ze

Erratum: Line transect surveying of arboreal monkeys: problems of group size and spread in a highly fragmented landscape

SF Ferrari, RRD Chagas, JP Souza-Alves
2011 American Journal of Primatology  
ERRATA Gonzalez-Zamora A, Arroyo-Rodríguez V, Chávez OM, Sánchez-López S, Stoner KE, Riba-Hernández P. 2009.  ...  In the article cited above, the reference to Morales Hernández [2004] was cited incorrectly. The correct citation is given below. Morales Hernández K. 2003.  ...  DOI: 10.1002/ajp.20935 Published online 11 February 2011 in Wiley Online Library ( r r 2011 Wiley-Liss, Inc.  ... 
doi:10.1002/ajp.20935 fatcat:u3hqacjdfzg5bk5bedepouzbx4

Page 964 of American Anthropologist Vol. 78, Issue 4 [page]

1976 American Anthropologist  
Hernandez, Carrol A., Marsha J. Haug, and Nathaniel N. Wagner, eds. Chicanos: Social and Psychological Perspectives. St. Louis: C. V. Mosby, 1976. xiii + 300 pp. $7.25 (paper). ISBN 0-8016-5316-9.  ...  Lisse, The Netherlands: Peter de Ridder, 1975. (Distributed in the U.S. by Bloomington Distribution Group, Bloom- ington, Indiana.) 17 pp. $.70, Dfl1.80 (paper). ISBN 90-316-0070-9.  ... 

Description d'un nouveau genre et de deux nouvelles especes d'Elaphidiini Thomson, 1864 d'Amerique Centrale (Coleoptera, Cerambycidae, Cerambycinae)

Alain Audureau
2021 Zenodo  
Hernandez leg. (AACP); 2♀♀, mêmes data (MEL); 1♀, Rio San Juan, Los Guatuzos, Rio Papaturro, 17-24.03.2000, J.M. Maes, J. Sunyer & B. Hernández leg. (AACP); 1♀, León, (UV trap), 25.03.1993, J.M.  ...  Néanmoins, le pronotum est lisse chez Maesicus gen. nov. et ne présente pas de tubercules comme Hemilissopsis.  ... 
doi:10.5281/zenodo.5518164 fatcat:iiegruxwwzgetohz4xcea7wi2m
« Previous Showing results 1 — 15 out of 1,992 results